Holen Sie sich die Stockscreener-App
56.74
1.53%
-0.88
Handel nachbörslich:
56.74
Schlusskurs vom Vortag:
$57.62
Offen:
$57.415
24-Stunden-Volumen:
618.72K
Relative Volume:
0.88
Marktkapitalisierung:
$4.37B
Einnahmen:
$754.05M
Nettoeinkommen (Verlust:
$73.06M
KGV:
62.54
EPS:
0.9073
Netto-Cashflow:
$164.23M
1W Leistung:
+5.37%
1M Leistung:
+16.22%
6M Leistung:
+44.97%
1J Leistung:
+104.25%
1-Tages-Spanne:
$56.09
$58.20
1-Wochen-Bereich:
$52.29
$58.20
52-Wochen-Spanne:
$24.85
$58.20
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
56.74 | 4.43B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026) - Minichart
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance - Yahoo Finance
Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor - TipRanks
Kiniksa Pharmaceuticals (KNSA) insider sale notice lists 58,424 shares - Stock Titan
Kiniksa (NASDAQ: KNSA) CSO Tessari resigns, signs $450/hour consulting deal - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan - Stock Titan
KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results - Insider Monkey
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in Stock - MarketBeat
Sanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed - Stock Titan
Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Maintained by Citigroup -- Price Target Raised to $60 - GuruFocus
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock - MarketBeat
Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan - Stock Titan
KNSA Maintained by Wedbush -- Price Target Raised to $59.00 - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) tops Q1 earnings and revenue estimates - MSN
KNSA Maintained by Wells Fargo -- Price Target Raised to $57 - GuruFocus
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation (KNSA) - Seeking Alpha
9 Best Drug Stocks to Buy According to Analysts - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earning - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High Following Strong Earnings - MarketBeat
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today - The Motley Fool
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued A - GuruFocus
Kiniksa Pharmaceuticals International Q1 2026 Earnings Call Transcript - MarketBeat
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today - The Motley Fool
KNSA Stock Soars 16.9% Following Recent Developments - GuruFocus
Kiniksa Pharmaceuticals (KNSA) Hits 52-Week High After Strong Q1 2026 Results - GuruFocus
KNSA Stock Jumps As Arcalyst Outlook Tops $1B Target - timothysykes.com
Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144 - Stock Titan
ARCALYST sales lift Kiniksa (NASDAQ: KNSA) Q1 2026 profit and cash - Stock Titan
KNSA Maintains Buy Rating -- Price Target Raised to $71.00 by Je - GuruFocus
KNSA Stock Rallies As Wedbush Hikes Price Target On Arcalyst Momentum - StocksToTrade
KNSA Stock Surges 19.3% Amid Positive Developments - GuruFocus
Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ) - Seeking Alpha
KNSA Stock Climbs As Arcalyst Momentum Fuels Bullish Targets - StocksToTrade
Kiniksa Pharmaceuticals International, plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KNSA) 2026-04-28 - Seeking Alpha
KNSA Stock Climbs As Analysts Hike Targets On Arcalyst Growth - timothysykes.com
Kiniksa Pharmaceuticals International Q1 Earnings Call Highlights - Yahoo Finance
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):